High Risk Localized Or Locally Advanced Prostate Cancer clinical trials

Explore recruiting high risk localized or locally advanced prostate cancer clinical trials.

Recruiting high risk localized or locally advanced prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

High Risk Localized Or Locally Advanced Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy

Belgium, Czechia, Sweden, Romania, Spain, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy (LUPUS)

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy

Spain, Netherlands, France, Germany, Italy, Czechia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

EORTC protocol 1414-ROG-GUCG: Phase IIIb randomized trial comparing irradiation plus long-term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG. Pegasus

Germany, Belgium, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

High Risk Localized Or Locally Advanced Prostate Cancer trials by city

High Risk Localized Or Locally Advanced Prostate Cancer in Toronto High Risk Localized Or Locally Advanced Prostate Cancer in Vancouver High Risk Localized Or Locally Advanced Prostate Cancer in Montreal High Risk Localized Or Locally Advanced Prostate Cancer in Calgary High Risk Localized Or Locally Advanced Prostate Cancer in Edmonton High Risk Localized Or Locally Advanced Prostate Cancer in Ottawa High Risk Localized Or Locally Advanced Prostate Cancer in Winnipeg High Risk Localized Or Locally Advanced Prostate Cancer in Quebec City High Risk Localized Or Locally Advanced Prostate Cancer in Hamilton High Risk Localized Or Locally Advanced Prostate Cancer in Kitchener High Risk Localized Or Locally Advanced Prostate Cancer in London High Risk Localized Or Locally Advanced Prostate Cancer in Halifax High Risk Localized Or Locally Advanced Prostate Cancer in New York High Risk Localized Or Locally Advanced Prostate Cancer in Los Angeles High Risk Localized Or Locally Advanced Prostate Cancer in Chicago High Risk Localized Or Locally Advanced Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease